Escrito por Dr Hannah K Shorrock Editado por Dr Larissa Nitschke Traduzido por Ana Carolina Martins Composto modificadores de “splicing” podem regular se a terapia gênica está ou não ativa A terapia gênica é uma estratégia terapêutica incrivelmente versátil que pode ser usada para tratar doenças monogênicas. A terapia gênica Read More…
Written by Alexandra Putka Edited by Dr. Hannah K Shorrock Improving neuron firing regularity rescued incoordination but not muscle weakness in a SCA1 mouse model. Spinocerebellar ataxias are characterized by problems within the cerebellum, the part of your brain responsible for balance, coordination, and walking. A central question within preclinical Read More…
Escrito por Kaitlyn Neuman Editado por Dra. Chandana Kondapalli Traduzido para o português por Priscila Pereira Sena Induzir a morte celular ou degradar mitocôndrias adoecidas – essa é a questão: um novo papel da ataxina-3 como mediadora dessa decisão. Você já ouviu alguém dizer: “Eu posso parecer não estar fazendo Read More…
Written by Dr. Hayley McLoughlin and Dr. Sharan Srinivasan Edited by Dr. Celeste Suart A novel genetic sequencing technology uncovered numerous familial ataxia cases linked to a unique mutation in an old genetic ataxia culprit. Despite improved access to genetic testing, the ability to diagnose hereditary ataxias remains quite difficult. Read More…
Written by Dr. Ambika Tewari Edited by Dr. Larissa Nitschke The abnormal activity of cells in the deep cerebellar nuclei and Purkinje cells correlate with the early onset of motor symptoms in a mouse model of SCA3 The cerebellum has an established role in maintaining balance and posture and coordinating Read More…
Escrito por Dr. Hannah K Shorrock Editado por Dr. Hayley McLoughlin e traduzido para o português por Ana Carolina Martins. Um modelo C. elegans de SCA3 ajuda a identificar o befiradol – agonista do receptor de serotonina – como um potencial terapêutico para SCA3 Para haver avanços com relação a Read More…
Written by Dr. Jorge Diogo Da Silva Edited by Dr. David Bushart How one research group assessed whether Rivastigmine, a Parkinson’s Disease drug, might have a role in treating SCA3 Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is the most common inherited ataxia worldwide. As with Read More…
Escrito por Carrie SheelerEditado por Dr. Hayley McLoughlin e traduzido para o português por Priscila Pereira Sena Pesquisadores usam ressonância magnética (RM) para determinar se o volume cerebral pode ser um marcador biológico para SCA3 Existem dois objetivos na pesquisa pré-clínica. Primeiro, entender a causa de uma doença. Segundo, desenvolver Read More…
Written by Dr Hannah K Shorrock Edited by Dr Larissa Nitschke Splice modifying compounds can regulate whether or not gene therapy is active Gene therapy is an incredibly versatile therapeutic strategy that can be used to treat monogenic disorders. Gene therapy can inactivate or silence mutant gene transcripts, edit the Read More…
Written by Kaitlyn NeumanEdited by Dr Chandana Kondapalli To induce cell death, or to degrade sick mitochondria – that is the question: a new role for ataxin-3 as a mediator of this decision. Have you ever heard the saying: “I may look like I’m not doing anything, but on a Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.
501(c)(3)
EIN 41-0832903
Mailing Address:
PO Box 27986
Golden Valley, MN 55427
Physical Address:
600 Highway 169 South
Suite 1725
Minneapolis, MN 55426
763-553-0020
763-553-0167 (Fax)
Sign up today to receive:
